心脏病学
比索洛尔
心肌梗塞
内科学
射血分数
β受体阻滞剂
危险系数
经皮冠状动脉介入治疗
医学
四分位间距
美托洛尔
临床终点
随机对照试验
置信区间
心力衰竭
作者
Troels Yndigegn,Bertil Lindahl,Katarina Mars,Joakim Alfredsson,Jocelyne Benatar,Lisa Brandin,David Erlinge,O. Hallén,Claes Held,Patrik Hjalmarsson,Pelle Johansson,Patric Karlström,Thomas Kellerth,Toomas Marandi,Annica Ravn-Fischer,Johan Sundström,Ollie Östlund,Robin Hofmann,Tomas Jernberg
标识
DOI:10.1056/nejmoa2401479
摘要
Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists.
科研通智能强力驱动
Strongly Powered by AbleSci AI